Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.
Elite Pharmaceuticals, Inc. develops, manufactures, and distributes niche generic pharmaceutical products, with product lines focused on immediate-release and controlled-release solid oral dose products. Company news commonly covers FDA approvals for abbreviated new drug applications, commercial launches under the Elite Laboratories label, and licensed distribution relationships with third-party pharmaceutical marketing organizations.
Recurring updates also include quarterly financial results, conference-call announcements, and operating commentary tied to generic product sales. Recent company developments have included methadone hydrochloride tablets, ropinirole extended-release tablets, lisdexamfetamine products, and naltrexone products within Elite's generic drug portfolio.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) has filed an Abbreviated New Drug Application (ANDA) with the US FDA for a generic drug in the antimetabolites class, which had reported annual sales of $42 million in the generic market for the year ending December 2022. This move reflects Elite's ongoing commitment to developing niche generic products. Elite Pharmaceuticals specializes in oral, controlled-release drug products and operates a cGMP and DEA registered facility in Northvale, NJ. The company previously licensed several generic products to partners such as Prasco, LLC and TAGI Pharma. Forward-looking statements in the release caution investors about risks and uncertainties regarding future performance and FDA approvals.